United States: The medical experts on the federal panel approved new recommendations regarding RSV vaccines for adult use in addition to a combined meningitis protection vaccine designed for teens.
More about the news
The director of the Centers for Disease Control and Prevention receives guidance from the 15-member panel about vaccine usage procedures.
The CDC lacks a permanent director at this moment, so one of their former prosecutors, now in a CDC role, will conduct the evaluation of Wednesday’s recommendations.
CDC Chief of Staff Matthew Buzzelli will make the decision, according to Health and Human Services spokesperson Andrew Nixon, AP News reported.
What are the experts’ recommendations?
A scientific panel offered these recommendations during their Wednesday meeting:
- The CDC acknowledges that adults between 50 and 59 years old with heart disease, diabetes, or chronic obstructive pulmonary disorder are eligible for respiratory syncytial virus vaccinations.
- The scientific panel approved a GSK-produced vaccine solution that protects from five types of meningococcal bacteria, which recently infected numerous college students approximately ten years ago. The new product would become one among various pharmaceutical agents that combat these organisms.
- The second chikungunya vaccine will become a candidate choice for Americans between ages 12 and older when they travel to regions with active outbreaks of the mosquito vector disease.
- Travelers from the United States develop chikungunya disease between 100 and 200 times per year. According to the panel, the new caution for the older chikungunya vaccine will instruct people who are 65 or older to carefully consider potential risks and the benefits of getting that vaccine version, as AP News reported.
After hearing about six illness reports connected to vaccination among seniors aged 65 and older who possessed additional medical conditions, the Board introduced safety guidance. The investigation is continuing.
